Table 2.
HRs for monotherapy failures with sulfonylurea (SU) versus metformin, and with meglitinide versus metformin, using 1:5 matching with propensity score for each comparison
| Monotherapy failure | Events | HR | ||
|---|---|---|---|---|
| Drugs | N (%) | (95% CI) | p Value | |
| Overall | SU | 717/400 (55.8) | 1.74 (1.56 to 1.94) | <0.001 |
| Metformin | 3585/1415 (39.5) | 1.0 | ||
| Add on | SU | 717/214 (29.9) | 3.14 (2.66 to 3.69) | <0.001 |
| Metformin | 3585/429 (12.0) | 1.0 | ||
| Switch | SU | 717/50 (7.0) | 2.81 (2.01 to 3.92) | <0.001 |
| Metformin | 3585/114 (3.2) | 1.0 | ||
| Add on+switch | SU | 717/264 (36.8) | 3.06 (2.65 to 3.56) | <0.001 |
| Metformin | 3585/543 (15.2) | 1.0 | ||
| Discontinuation | SU | 717/136 (19.0) | 0.94 (0.79 to 1.13) | 0.5 |
| Metformin | 3585/872 (24.3) | 1.0 | ||
| Overall | Meglitinide | 218/136 (62.4) | 1.66 (1.37 to 2.00) | <0.001 |
| Metformin | 1090/503 (46.2) | 1.0 | ||
| Add on | Meglitinide | 218/65 (29.8) | 2.52 (1.89 to 3.37) | <0.001 |
| Metformin | 1090/163 (15.0) | 1.0 | ||
| Switch | Meglitinide | 218/23 (10.6) | 3.78 (2.25 to 6.32) | <0.001 |
| Metformin | 1090/40 (3.7) | 1.0 | ||
| Add on+switch | Meglitinide | 218/88 (40.4) | 2.76 (2.15 to 3.55) | <0.001 |
| Metformin | 1090/203 (18.6) | 1.0 | ||
| Discontinuation | Meglitinide | 218/48 (22.0) | 0.95 (0.70 to 1.29) | 0.7 |
| Metformin | 1090/300 (27.5) | 1.0 |